Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGENDA: Dacarbazine With or Without Genasense (oblimersen) in Advanced Melanoma With Low LDH
2007-003340-30Phase 3Completed
- Sponsor
- Genta Incorporated
- Start
- Aug 2007
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Dacarbazine + Genasense with Dacarbazine + placebo (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Aug 2007; status: completed.
02
Drugs
oblimersen
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-003340-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003340-30.